ENVB
Enveric Biosciences, Inc.
There isn't enough reported data to score ENVB yet.
ENVB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ENVB's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ENVB PE Valuation
ENVB has no meaningful PE right now: it lost money over the past year.
ENVB Forward outlook
There aren't enough analyst estimates for ENVB to show an outlook.
ENVB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.55 | +$109.18 |
| Q1 2026 | -$36.43 | +$131.66 |
| Q4 2025 | -$49.99 | +$213.26 |
| Q3 2025 | -$102.34 | +$354.86 |
| Q2 2025 | -$134.73 | +$513.27 |
| Q1 2025 | -$168.09 | +$982.11 |
| Q4 2024 | -$263.25 | +$1,192.95 |
| Q3 2024 | -$457.20 | +$2,305.80 |
ENVB lost $25.55 per share over the past year, a smaller loss than the year before.
ENVB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2020 | $8.5M | -7.3% |
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2020 | -13% | +3.9 points |
| Q2 2020 | -14% | N/A |
| Q1 2020 | -17% | N/A |
| Q4 2019 | -22% | N/A |
| Q3 2019 | -17% | N/A |
ENVB's operating margin was −13% last quarter, up 3.9 points from the same quarter a year ago.
ENVB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.4M | -$554.4K |
| Q1 2026 | -$2.3M | +$134.7K |
| Q4 2023 | -$1.8M | +$1.7M |
| Q3 2023 | -$2.7M | +$1.8M |
| Q2 2023 | -$4.5M | +$173.1K |
| Q1 2023 | -$5.1M | -$87.7K |
| Q4 2022 | -$3.5M | +$599K |
| Q3 2022 | -$4.6M | -$2.4M |
ENVB has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
ENVB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +164% | +2.5M shares |
| 1 year | +1743% | +3.8M shares |
| 3 years | +33951% | +4M shares |
| 5 years | +623857% | +4M shares |
| Available history | +6645040% | +4M shares |
ENVB has 4M diluted shares, up 1743% from a year ago.
ENVB Net Leverage
ENVB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ENVB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.3 | Neutral |
| Stochastic | 53.9 | Neutral |
ENVB's weekly RSI is 41 (neutral) and its Stochastic is 54 (neutral).
ENVB PE vs Healthcare Sector
ENVB has no meaningful PE right now: it lost money over the past year.
ENVB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.45 | 4.8% above |
| 20 week MA | $1.45 | 4.8% above |
| 50 week MA | $2.33 | 35% below |
| 100 week MA | $11.2 | 86% below |
| 200 week MA | $141.9 | 99% below |
ENVB has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 99% below its 200-week average.
ENVB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $86,400.0 | $60,840.0 | -30% |
| 2021 | $60,840.0 | $9,630.0 | -84% |
| 2022 | $9,630.0 | $316.8 | -97% |
| 2023 | $316.8 | $234.0 | -26% |
| 2024 | $234.0 | $62.5 | -73% |
| 2025 | $62.5 | $4.11 | -93% |
| 2026 YTD | $4.11 | $1.52 | -63% |
ENVB has finished every year since 2020 lower, and it's down 63% so far in 2026.